马拉维布兰太尔2006-18年13价肺炎球菌结合疫苗对疫苗和非疫苗血清型侵袭性肺炎球菌病发病率的影响与效果:前瞻性观察时间序列和病例对照研究
该研究在马拉维布兰太尔通过前瞻性观察时间序列和病例对照研究,评估2011年引入PCV13后对疫苗和非疫苗血清型侵袭性肺炎球菌病的影响。结果显示PCV13前已有发病率下降趋势,接种后疫苗血清型病在1-4岁和5-14岁儿童中分别较反事实预测下降74%和79%,但婴儿和成人间接保护有限。
要点
- PCV13引入前婴儿和1-4岁儿童侵袭性肺炎球菌病发病率已下降。
- 接种后1-4岁和5-14岁儿童疫苗血清型病分别下降74%和79%。
- 婴儿和成人未接种者间接保护效果不显著。
核心结论
- 在高死亡率高HIV流行地区,PCV13引入前侵袭性肺炎球菌病发病率已有下降。
- 接种7年后疫苗适龄儿童疫苗血清型病显著下降,但未接种婴儿和成人间接保护不显著。
- 政策应考虑多种替代策略,包括免疫规划外针对性接种以保护脆弱人群。
研究设计与样本
- 监测覆盖10 281 476人年,包含140 498份血液和63 291份脑脊液培养。
- 病例对照研究纳入19例疫苗适龄侵袭性肺炎球菌病病例和76名匹配社区对照。
主要发现
- 总侵袭性肺炎球菌病发病率在PCV引入前已下降:婴儿<1岁下降19%(IRR 0·81,95%CI 0·74-0·88,p<0·0001),1-4岁下降14%(0·86,0·80-0·93,p<0·0001)。
- 青少年和成人≥15岁下降8%(0·92,0·83-1·01,p=0·084),5-14岁儿童增加2%(1·02,0·93-1·11,p=0·72)。
- 与反事实预测相比,接种后疫苗血清型病在1-4岁儿童下降74%(95%CI 70-78),5-14岁下降79%(76-83),婴儿下降38%(37-40),青少年和成人下降47%(44-51)。
- 2015年以来非疫苗血清型侵袭性肺炎球菌病发病率增加,但观察到的发病率仍低。
- 病例对照研究显示疫苗对疫苗血清型侵袭性肺炎球菌病的有效性为80·7%(-73·7至97·9)。
临床怎么用
- 在高死亡率高HIV流行地区,应评估PCV13对未接种婴儿和成人的间接保护不足。
- 政策制定可考虑免疫规划外针对性接种以保护脆弱人群。
局限性
- 病例对照研究样本量小(19例病例和76名对照),疫苗有效性置信区间宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The population impact of pneumococcal conjugate vaccines (PCVs) depends on direct and indirect protection. Following Malawi's introduction of the 13-valent PCV (PCV13) in 2011, we examined its impact on vaccine and non-vaccine serotype invasive pneumococcal disease among vaccine-eligible-age and vaccine-ineligible-age children and adults. METHODS: We did a prospective observational time-series analysis and a case-control study. We used data from between Jan 1, 2006, and Dec 31, 2018, from laboratory-based surveillance at a government hospital in Malawi. This period included 6 years before and 7 years after introduction of PCV13. By use of negative-binomial regression, we evaluated secular trend-adjusted incidence rate ratio (IRR) in vaccine serotype and non-vaccine serotype invasive pneumococcal disease before and after introduction of PCV. We compared predicted counterfactual incidence in hypothetical absence of vaccine with empirically observed incidence following vaccine introduction. The case-control study assessed vaccine effectiveness, comparing PCV uptake among cases of vaccine-eligible-age invasive pneumococcal disease versus matched community controls. FINDINGS: Surveillance covered 10 281 476 person-years of observation, with 140 498 blood and 63 291 cerebrospinal fluid cultures. A reduction in total (vaccine serotype plus non-vaccine serotype) invasive pneumococcal disease incidence preceded introduction of PCV: 19% (IRR 0·81, 95% CI 0·74 to 0·88, p<0·0001) among infants (<1 year old), 14% (0·86, 0·80 to 0·93, p<0·0001) among children aged 1-4 years, and 8% (0·92, 0·83 to 1·01, p=0·084) among adolescents and adults (≥15 years old). Among children aged 5-14 years there was a 2% increase in total invasive pneumococcal disease (1·02, 0·93 to 1·11, p=0·72). Compared with the counterfactually predicted incidence, incidence of post-PCV13 vaccine serotype invasive pneumococcal disease was 74% (95% CI 70 to 78) lower among children aged 1-4 years and 79% (76 to 83) lower among children aged 5-14 years, but only 38% (37 to 40) lower among infants and 47% (44 to 51) lower among adolescents and adults. Although non-vaccine serotype invasive pneumococcal disease has increased in incidence since 2015, observed incidence remains low. The case-control study (19 cases and 76 controls) showed vaccine effectiveness against vaccine serotype invasive pneumococcal disease of 80·7% (-73·7 to 97·9). INTERPRETATION: In a high-mortality, high-HIV-prevalence setting in Africa, there were significant pre-vaccine reductions in the incidence of invasive pneumococcal disease. 7 years after PCV introduction, although vaccine-attributable impact among vaccine-eligible-age children was significant, indirect effects benefitting unvaccinated infants and adults were not. Policy decisions should consider multiple alternative strategies for reducing disease burden, including targeted vaccination outside infant Expanded Programme of Immunization to benefit vulnerable populations. FUNDING: Bill & Melinda Gates Foundation, Wellcome Trust, and National Institute for Health Research.
引用
- Bar-Zeev N, Swarthout TD, Everett DB, et al. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies. Lancet Glob Health. 2021. PMID: 34143997. doi:10.1016/S2214-109X(21)00165-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。